Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Lilly follows fellow drugmaker Johnson & Johnson, who sued the Health and Human Services Department on Tuesday, accusing the ...

Oil prices fell on Friday on signs demand in China, the world's biggest crude importer, continues to underperform amid its ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...